Longeveron Inc. LGVN
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- -64.82%
- 1 year
- -77.75%
- Market cap
- 5.67M
- Revenue (ttm)
- 1.23M
- EPS (ttm)
- -9.90
- Shares out
- 13.35M
- Forward P/E
- -1.16
- YTD return
- -64.82%
- 1-year return
- -77.75%
- Volume
- 61.41K
- Avg volume
- 106.52K
- Open
- 1.76
- Previous close
- 1.78
- Day's range
- 1.75 – 1.82
- 52-week range
- 1.31 – 12.30
- Beta
- 0.35
- Price target
- 8.88 (+398.6%)
- Earnings date
- Aug 14, 2024
5D -0.01 (-0.56%)
Key statistics
- Enterprise value
- 22.40M
- PEG ratio
- 0.00
- Price / sales
- 21.37
- Price / book
- 0.66
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 115.70%
- Free cash flow
- -10.03M
- Total cash
- 12.38M
- Total debt
- 1.75M
- Return on equity
- -142.16%
- Short % of float
- 10.24%
- 50-day average
- 2.01
- 200-day average
- 2.26
Analyst view
- Target (low)
- 6.00
- Target (mean)
- 8.88
- Target (high)
- 10.00
- Strong buy3
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.53 | -0.34 | +0.19 | +35.85% |
| Aug 14, 2024 | Jun 1, 2024 | -1.03 | -1.83 | -0.80 | -77.67% |
| Aug 14, 2024 | Jun 1, 2024 | -1.03 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -2.01 | -1.61 | +0.40 | +19.90% |
| May 14, 2024 | Mar 1, 2024 | -2.01 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | -2.10 | -2.50 | -0.40 | -19.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 27, 2024 | Maxim Group | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- longeveron.com
News
Your note
Sign in to keep a note on LGVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGAFONOVA NATALIYA | Officer | Stock Award(Grant) | Aug 14, 2024 | 163,130 |
| BALUCH KHOSO | Director | Sale | Dec 1, 2024 | 23,750 |
| HARE JOSHUA M | Officer, Director and Beneficial Owner | Stock Award(Grant) | Aug 14, 2024 | 727,046 |
| HARE NEIL E | Director | Stock Award(Grant) | Aug 14, 2024 | 30,246 |
| HASHAD MOHAMED WA'EL AHMED | Chief Executive Officer | Stock Award(Grant) | Aug 14, 2024 | 90,368 |
| KENDER RICHARD N | Director | Stock Award(Grant) | May 9, 2024 | 16,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.97% | 128,947 | 228.24K | Sep 29, 2024 |
| Vanguard Group Inc | 0.34% | 44,984 | 79.62K | Sep 29, 2024 |
| Capital Investment Advisory Services, LLC | 0.20% | 26,525 | 46.95K | Sep 29, 2024 |
| State Street Corporation | 0.11% | 15,180 | 26.87K | Sep 29, 2024 |
| Creative Planning | 0.08% | 11,200 | 19.82K | Sep 29, 2024 |
| Blackrock Inc. | 0.08% | 10,016 | 17.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 72,197 | 127.79K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.34% | 44,984 | 79.62K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 24,137 | 42.72K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 17,087 | 30.24K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,572 | 6.32K | Oct 30, 2024 |